← All trials
NCT00395161
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2007
- Primary completion
- Nov 1, 2009
- Completion date
- Nov 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 293
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of UtahLead sponsor
- University of PittsburghOverall official - principal investigator
- University of UtahSponsor investigator
- University of PittsburghCollaborator
- University of California, Los AngelesCollaborator
- University of MichiganCollaborator
- Children's National Medical CenterCollaborator
- University of Southern CaliforniaCollaborator
- University of WashingtonCollaborator
- Harborview Injury Prevention and Research CenterCollaborator
- National Institutes of Health (NIH)Collaborator
- University of ArkansasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.